Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2

Tumor histology affects the real-world effectiveness of first line ET plus CDK4/6i. In ILC, all three CDK4/6i performed similarly; therefore, treatment selection should prioritize tolerability, manageability, drug-drug interactions, and patient preferences.

Authors

Institutions

Publication Details

Journal
The Breast
Published
2026-01-03
DOI
https://doi.org/10.1016/j.breast.2026.104692
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2

Carmen Criscitiello, Gianpiero Rizzo, Donata Sartori, Giuseppe Curigliano et al.
The Breast
Advanced Breast Cancer Therapies
article

Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2

Carmen Criscitiello, Gianpiero Rizzo, Donata Sartori, Giuseppe Curigliano, Francesca Ligorio, G Armani, Christian Zurlo, Giacomo Mazzoli, Monica Giordano, Angela Toss, Simona Pisegna, Alberto Zambelli, Valentina Guarneri, Grazia Arpino, Andrea Botticelli, Simone Scagnoli, Vinny Faso, Ambra Carnevale Schianca, Alessandra Gennari, Alice Menichetti, Camilla Capasso, Marianna Sirico, Barbara Tagliaferri, Antonio Marra, Marta Piras, Matteo De Monte, Gaia Griguolo, Giancarlo Pruneri, Rebecca Pedersini, Edoardo Chiappe, Daniele Generali, Giuseppe Fotia, Mario Giuliano, Maria Vittoria Dieci, Flavia Jacobs, Matteo Lambertini, Nicla La Verde, Carmine De Angelis, Luigi Mariani, Leonardo Provenzano, Elisabetta Munzone
article en

Abstract

Tumor histology affects the real-world effectiveness of first line ET plus CDK4/6i. In ILC, all three CDK4/6i performed similarly; therefore, treatment selection should prioritize tolerability, manageability, drug-drug interactions, and patient preferences.

The BreastVol. 86
University of Modena and Reggio Emilia (IT), Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), Vita-Salute San Raffaele University (IT), Istituti Clinici Scientifici Maugeri (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Ospedale Papa Giovanni XXIII (IT), Istituto Oncologico Veneto (IT), Azienda Ospedaliera Sant'Andrea (IT), Azienda Socio Sanitaria Territoriale Lariana (IT), Ospedale di Mirano (IT), Ospedale Policlinico San Martino (IT), Policlinico San Matteo Fondazione (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), ASST Fatebenefratelli Sacco (IT), Istituti Ospitalieri di Cremona (IT), Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT), European Institute of Oncology (IT), University of Naples Federico II (IT), Sapienza University of Rome (IT)
European Commission, Ministero della Salute, Associazione Italiana per la Ricerca sul Cancro
Good health and well-being
Openalex Percentile: Top 99%
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.